Inotuzumab (Anti-Siglec-2 / CD22)

Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. The antibody-drug conjugate (ADC) Inotuzumab ozogamicin, sold under the brand name Besponsa, is a targeted cancer therapeutics used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This ADC drug is a conjugate that combines a monoclonal antibody Inotuzumab with a cytotoxic agent called calicheamicin through linker. This biosimilar antibody is used for research only. MW: 144.78 kD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG4
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human CD22
Clone	Inotuzumab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	144.78 kD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0